Innovent Biologics and Eli Lilly expand global drug development partnership for oncology and immunology

prnasia.com (Chinese)

Innovent Biologics and Eli Lilly have formed a global strategic partnership to advance novel drug development in oncology and immunology. This marks their seventh collaboration, leveraging complementary strengths. Innovent will lead early-stage research in China, while Lilly secures global rights outside Greater China, with Innovent eligible for up to $8.5 billion in milestone payments. The deal includes a $350 million upfront payment for Innovent and royalty payments on future sales, further solidifying their long-standing partnership.


With a significance score of 3.3, this news ranks in the top 9.5% of today's 31096 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Innovent Biologics and Eli Lilly expand global drug development partnership for oncology and immunology | News Minimalist